Biodexa Pharmaceuticals PLC held a General Meeting where all proposals were approved. The proposals included reducing the nominal value per ordinary share and granting the Directors the authority to allot ordinary shares on a non-pre-emptive basis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.